PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

• 主要な著者: Jayaprakasam Bolleddula (著者), Alice Ke (著者), Hua Yang (著者), Chandra Prakash (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2021-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Ivosidenib is a potent, targeted, orally active, small‐molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that has been approved in the United States for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are greater than or equal to 75 years of age or...